Abu Dhabi,United Arab Emirates, June 7, 2024 /PRNewswire/ — At the BIO 2024 International Conference, Ministry of Public Health – Abu Dhabi (DoH), Novartis Middle East, the UAE’s healthcare sector regulator, has signed a Memorandum of Understanding (MoU) with global pharmaceutical company Novartis Middle East FZE. Under the terms of the MoU, the two companies will collaborate to advance solutions across multiple therapeutic areas. Two priority focus areas include advancing clinical genomics research for real-world evidence (RWE) and generating and disseminating evidence to support the understanding of radioligand therapy (RLT) for cancer patients.
DoH and Novartis partner to advance genomic research in oncology and beyond
In the presence of Thierry DiaganaDr. Asma Ibrahim Al ManaeiExecutive Director of the Ministry of Health Research and Innovation Centre; Ibrahim AquelHead of Government Relations and Value & Access, Gulf Region, Novartis.
In this collaboration, Abu Dhabi Bringing together their expertise in genomics and a forward-thinking, agile regulatory framework research hub, they will collaborate on future clinical research and RWE generation, including exploring innovative solutions and genomics research in oncology, cardiovascular disease, and neuroscience. They will also collaborate to generate and disseminate evidence with key stakeholders to support the recognition and understanding of RLT, a form of precision nuclear medicine that can recognize and treat disease in patients with advanced cancer.
doctor Asma Ibrahim Al Manaei “Novartis is a long-standing partner of the Ministry of Health and we are proud to explore new opportunities to work together for the ultimate benefit of patients in the region and beyond.
This collaboration will enable us to further accelerate the fields of personalized and precision medicine in important therapeutic areas. Abu Dhabi As a global life sciences hub and center of innovative research, we are pleased to collaborate with our strategic partners and pool our expertise in pursuit of our common goals.”
Novartis and the Ministry of Health will explore innovative solutions to local and regional health needs, including collaborating to raise awareness of genetic and rare diseases and supporting the Emirati Genomics Programme. A final focus area will be to help further improve health technology assessment through fostering partnerships and sharing of best practices.
Mohammed Ezz Eldin Head The Gulf representative for Novartis said: “We are pleased to announce our collaboration with the Ministry of Health. Abu Dhabi Through the signing of this MoU, Novartis has achieved a significant milestone in advancing research and innovation in healthcare, particularly in the areas of oncology, cardiovascular disease and neuroscience. Abu Dhabi“The aim of this project is to generate real-world evidence and raise awareness about radioligand therapy and we look forward to working closely with the Department of Health.” Abu Dhabi “To drive innovation and strengthen the region’s health technology assessment capacity. Our goal is to contribute to personalized and precision medicine, and ultimately improve patient outcomes.”
Led by the Ministry of Health Abu Dhabi (DoH), a well-known Abu Dhabi The delegation, led by Chairman of the Ministry of Health Mansour Ibrahim Al Mansouri, is on the visit. united states of america (united states of america) while May 29Number2024 and June 5NumberIt will showcase Emirati partnership opportunities in 2024 and explore collaborations with leading research and development (R&D), manufacturing and innovation organizations. PhiladelphiaThe delegation met with existing and new partners and forged collaborations with leading educational and research institutions, government agencies and medical technology giants. The international mission: San Diegoin agreement with Abu Dhabi We will participate in the BIO International Convention 2024 to showcase the growth and development of the UAE’s biotech industry.
The participation led to in-depth discussions, sharing of insights and expertise, and exploring collaborations in health tech, life sciences and innovation.
Photo – https://mma.prnewswire.com/media/2432775/DoH_and_Novartis.jpg
